DICE Therapeutics (DICE) PT Raised to $54 at Stifel
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
Go back to DICE Therapeutics (DICE) PT Raised to $54 at Stifel
October 11, 2022 12:23 PM EDT
H.C. Wainwright analyst Emily Bodnar raised the price target on DICE Therapeutics (NASDAQ: DICE) to $60.00 (from $40.00) while maintaining a Buy rating.
...
More
October 11, 2022 12:10 PM EDT
SVB Leerink analyst Thomas Smith raised the price target on DICE Therapeutics (NASDAQ: DICE) to $77.00 (from $46.00) while maintaining a Outperform rating.
...
More
October 11, 2022 11:30 AM EDT
Cantor Fitzgerald analyst Prakhar Agrawal raised the price target on DICE Therapeutics (NASDAQ: DICE) to $68.00 (from $36.00) while maintaining a Overweight rating.
...
More
October 11, 2022 11:29 AM EDT
Evercore ISI analyst Josh Schimmer raised the price target on DICE Therapeutics (NASDAQ: DICE) to $75.00 (from $45.00) while maintaining a Outperform rating.
...
More
October 11, 2022 7:01 AM EDT
DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, today announced positive topline data from its Phase 1 clinical trial of DC-806, an oral small molecule antagonist of the pro-inflammatory cytokine IL-17. The trial was a first-in-human, randomized, double-blind, placebo-controlled study designed to generate safety and pharmacokinetic (PK) data in healthy volunteers as well as provide early clinical proof-of-concept in psoriasis patients. The trial was conducted in three overlapping parts: Phase 1a... More
